MIFEPRISTONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C29H35NO2
Molecular Weight	429.5937
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C5=CC=C(C=C5)N(C)C

InChI

InChIKey=VKHAHZOOUSRJNA-GCNJZUOMSA-N

InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C29H35NO2
Molecular Weight	429.5937
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00834
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/cdi/mifepristone.html

Mifepristone is a synthetic steroid with antiprogestational effects indicated for the medical termination of intrauterine pregnancy through 49 days' pregnancy. Doses of 1 mg/kg or greater of mifepristone have been shown to antagonize the endometrial and myometrial effects of progesterone in women. During pregnancy, the compound sensitizes the myometrium to the contraction-inducing activity of prostaglandins. Mifepristone also exhibits antiglucocorticoid and weak antiandrogenic activity. The activity of the glucocorticoid dexamethasone in rats was inhibited following doses of 10 to 25 mg/kg of mifepristone. Doses of 4.5 mg/kg or greater in human beings resulted in a compensatory elevation of adrenocorticotropic hormone (ACTH) and cortisol. The anti-progestational activity of mifepristone results from competitive interaction with progesterone at progesterone-receptor sites. Based on studies with various oral doses in several animal species (mouse, rat, rabbit and monkey), the compound inhibits the activity of endogenous or exogenous progesterone. The termination of pregnancy results. In the treatment of Cushing's syndrome, Mifepristone blocks the binding of cortisol to its receptor. It does not decrease cortisol production but reduces the effects of excess cortisol, such as high blood sugar levels. Mifepristone is used for the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Progesterone receptor 61 Target ID: CHEMBL208 Sources: http://www.drugbank.ca/drugs/DB00834	Antagonist 2849	0.35 nM [IC50]
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: http://www.drugbank.ca/drugs/DB00834	Antagonist 2849	0.8 nM [IC50]
Androgen Receptor 169 Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8627601	Antagonist 2849	5.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Intrauterine pregnancy through 70 days gestation 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf	Curative		Approved 8583	MIFEPREX Approved Use MIFEPREX is indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation. Launch Date 2000

C_max

Value	Dose	Co-administered	Analyte	Population
3.8 μM REVIEW https://pubmed.ncbi.nlm.nih.gov/11858883/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		MIFEPRISTONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: FEMALE food status: UNKNOWN
1.77 mg/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		MIFEPRISTONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
25.8 mg × h/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		MIFEPRISTONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
85 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202107s008lbl.pdf	600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	MIFEPRISTONE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: FED
25 h REVIEW https://pubmed.ncbi.nlm.nih.gov/11858883/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	MIFEPRISTONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: FEMALE food status: UNKNOWN
18 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	MIFEPRISTONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
0.8% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202107s008lbl.pdf	600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:		MIFEPRISTONE plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: FED
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		MIFEPRISTONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP3A 227 CYP2C8 1057 CYP2B6 926 CYP1A2 2153 CYP2A6 879 CYP2C19 2057 CYP2E1 1060 P-gp 1741 BCRP 910 OATP1B1 1079 OATP1B3 961 OATP2B1 157 OCT1 620 NTCP 39 BSEP 550	CYP2B 10 CYP2C 16 P-gp 2052 BCRP 697	CYP3A 142

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=26 Page: 26.0	inconclusive [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=26 Page: 26.0	inconclusive [IC50 >10 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=26 Page: 26.0	no
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=26 Page: 26.0	no
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	yes [IC50 1 uM]
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=32 Page: 32.0	yes [IC50 1.8 uM]		yes (co-administration study) Comment: The sponsor reported that Cmax values of digoxin were increased when digoxin was administered with the first dose (ratio, 1.68, CI, 1.54-1.84) and the last dose of mifepristone (ratio, 1.64, CI, 1.50-1.79). Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=32 Page: 32.0
BSEP 554	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=102 Page: 102.0	yes [IC50 3 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0	yes [IC50 3 uM]	RU 42698 1	yes (co-administration study) Comment: The first and last multiple doses of mifepristone 1200 mg/day for 7 days produced 2.67- fold and 3.57 fold increase, respectively, in fluvastatin AUC0-24. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0	yes [IC50 3.5 uM]	RU 42633 1	yes (co-administration study) Comment: The first and last multiple doses of mifepristone 1200 mg/day for 7 days produced 2.67- fold and 3.57 fold increase, respectively, in fluvastatin AUC0-24. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0
OATP2B1 162	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	yes [IC50 4.3 uM]
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=32 Page: 32.0	yes [IC50 5.6 uM]
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0	yes [IC50 6.7 uM]	RU 42848 1	yes (co-administration study) Comment: The first and last multiple doses of mifepristone 1200 mg/day for 7 days produced 2.67- fold and 3.57 fold increase, respectively, in fluvastatin AUC0-24. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0
OCT1 656	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	yes [IC50 67 uM]
NTCP 40	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	yes [IC50 70 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0	yes [IC50 8.5 uM]	RU 42698 1
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0	yes [IC50 8.5 uM]	RU 42698 1
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202107s008lbl.pdf#page=11 Page: 11.0	yes [IC50 8.6 uM]		yes (co-administration study) Comment: The first and last multiple doses of mifepristone 1200 mg/day for 7 days produced 2.67- fold and 3.57 fold increase, respectively, in fluvastatin AUC0-24. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202107s008lbl.pdf#page=11 Page: 11.0
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0	yes [IC50 8.6 uM]	RU 42633 1	yes (co-administration study) Comment: AUC0-72 hr of alprazolam and 4-OH alprazolam following 1 mg of alprazolam increased 80% (n=16) and 76% (n=16) , respectively with concomitant administration of multiple doses of 1200 mg/day mifepristone for 10 days compared to those following 1 mg of alprazolam alone. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0	yes [IC50 8.7 uM]	RU 42698 1	yes (co-administration study) Comment: AUC0-72 hr of alprazolam and 4-OH alprazolam following 1 mg of alprazolam increased 80% (n=16) and 76% (n=16) , respectively with concomitant administration of multiple doses of 1200 mg/day mifepristone for 10 days compared to those following 1 mg of alprazolam alone. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=33 Page: 33.0
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=34 Page: 34.0	yes [IC50 9.1 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202107s008lbl.pdf#page=11 Page: 11.0	yes [IC50 >10 uM]		yes (co-administration study) Comment: The first and last multiple doses of mifepristone 1200 mg/day for 7 days produced 2.67- fold and 3.57 fold increase, respectively, in fluvastatin AUC0-24. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202107s008lbl.pdf#page=11 Page: 11.0
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=26 Page: 26.0	yes [IC50 >50 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=25 Page: 25.0	yes [Ki 4.7 uM]		yes (co-administration study) Comment: AUC0-72 hr of alprazolam and 4-OH alprazolam following 1 mg of alprazolam increased 80% (n=16) and 76% (n=16) , respectively with concomitant administration of multiple doses of 1200 mg/day mifepristone for 10 days compared to those following 1 mg of alprazolam alone. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=25 Page: 25.0
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202107s008lbl.pdf#page=11 Page: 11.0	yes
CYP3A 317	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=26 Page: 26.0	yes
CYP3A 317	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202107s008lbl.pdf#page=10 Page: 10.0	yes

Drug as victim

Target	Modality	Activity
CYP2B 10	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=25 Page: 25.0	minor
CYP2C 16	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=25 Page: 25.0	minor
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	yes
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202107s008lbl.pdf#page=15 Page: 15.0	yes
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000ClinPharmR.pdf#page=10 Page: 10.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=18 Page: 18.0
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000PharmR.pdf#page=18 Page: 18.0		RU42848 1

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:50692	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50692
ChemicalBook	CB6351940	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6351940
eMolecules	29563088	https://www.emolecules.com/cgi-bin/more?vid=29563088
eMolecules	30154688	https://www.emolecules.com/cgi-bin/more?vid=30154688
eMolecules	592261	https://www.emolecules.com/cgi-bin/more?vid=592261
MolPort	MolPort-003-849-222	https://www.molport.com/shop/molecule-link/MolPort-003-849-222
Selleck Chemicals	Mifepristone(Mifeprex)	http://www.selleckchem.com/products/Mifepristone(Mifeprex).html
ZINC	ZINC000003831128	http://zinc15.docking.org/substances/ZINC000003831128

PubMed

Title	Date	PubMed
Progestin activation of nongenomic pathways via cross talk of progesterone receptor with estrogen receptor beta induces proliferation of endometrial stromal cells.	2005-12	16020483
Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis.	2005-11	16049126
Enhanced dopamine uptake in the striatum following repeated restraint stress.	2005-09-01	15945060
Pathophysiology of mifepristone-induced septic shock due to Clostridium sordellii.	2005-09	16046483
Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells.	2005-09	15932931
CAR and PXR: xenosensors of endocrine disrupters?	2005-08-15	16054614
Dissociated glucocorticoids equipotently inhibit cytokine- and cAMP-induced matrix degrading proteases in rat mesangial cells.	2005-08-01	15963473
Induction of thymocyte apoptosis by systemic administration of concanavalin A in mice: role of TNF-alpha, IFN-gamma and glucocorticoids.	2005-08	16047339
Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage.	2005-08	16045524
Monoamine oxidase-A is a major target gene for glucocorticoids in human skeletal muscle cells.	2005-08	15946989
Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.	2005-08	15860655
Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects.	2005-08	15845615
Clostridium sordellii toxic shock syndrome after medical abortion with mifepristone and intravaginal misoprostol--United States and Canada, 2001-2005.	2005-07-29	16049422
Discovery of non-steroidal mifepristone mimetics: pyrazoline-based PR antagonists.	2005-07-01	15925510
Effect of mifepristone on proliferation and apoptosis of Ishikawa endometrial adenocarcinoma cells.	2005-07	16009178
The effects of cortisol administration on social status and brain monoaminergic activity in rainbow trout Oncorhynchus mykiss.	2005-07	16000540
The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.	2005-06	15870863
Progesterone induces the fibulin-1 expression in human endometrial stromal cells.	2005-06	15774544
Corticosteroids inhibit cell death induced by doxorubicin in cardiomyocytes: induction of antiapoptosis, antioxidant, and detoxification genes.	2005-06	15755911
Ligand-selective targeting of the glucocorticoid receptor to nuclear subdomains is associated with decreased receptor mobility.	2005-06	15705660
Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8 production via nuclear factor kappa B inactivation in endometriotic stromal cells.	2005-05	15866594
G-CSF, but not corticosterone, mediates circulating neutrophilia induced by febrile-range hyperthermia.	2005-05	15829718
Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway.	2005-05	15684043
Behavioral stress enhances hippocampal CA1 long-term depression through the blockade of the glutamate uptake.	2005-04-27	15858055
Conditional regulation of the human CYP4X1 and CYP4Z1 genes.	2005-04-15	15797250
Characterization of a critical region in the hormone binding domain of sperm progesterone receptor.	2005-04	15811074
Lack of synergy between estrogen and progesterone on local IGF-I, IGFBP-3 and IGFBP-2 secretion by both hormone-dependent and hormone-independent breast cancer explants in vitro. Effect of tamoxifen and mifepristone (RU 486).	2005-04	15809018
Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion.	2005-04	15793248
Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications.	2005-03-26	15790602
Role of activation function domain-1, DNA binding, and coactivator GRIP1 in the expression of partial agonist activity of glucocorticoid receptor-antagonist complexes.	2005-03-08	15736964
Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling.	2005-03-03	15674352
Inhibition of tristetraprolin expression by dexamethasone in activated macrophages.	2005-03-01	15710351
15-Hydroxyprostaglandin dehydrogenase can be induced by dexamethasone and other glucocorticoids at the therapeutic level in A549 human lung adenocarcinoma cells.	2005-03-01	15680906
The putative tumor suppressor deleted in malignant brain tumors 1 is an estrogen-regulated gene in rodent and primate endometrial epithelium.	2005-03	15564322
Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids.	2005-02-01	15629111
p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.	2005-02	15860260
Progesterone increases tissue factor gene expression, procoagulant activity, and invasion in the breast cancer cell line ZR-75-1.	2005-02	15562024
The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice.	2005-02	15456840
Characterization of thymic atrophy and the mechanism of thymocyte depletion after in vivo exposure to a mixture of herbicides.	2005-01-22	15762548
A comparison of in vitro and in vivo EDSTAC test battery results for detecting antiandrogenic activity.	2005-01-01	15589981
Novel progestogenic activity of environmental endocrine disruptors in the upregulation of calbindin-D9k in an immature mouse model.	2005-01	15509668
High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line.	2005-01	15466163
Glucocorticoid receptor involvement in pair bonding in female prairie voles: the effects of acute blockade and interactions with central dopamine reward systems.	2005	15961248
Glucocorticoid receptor antagonists: new tools to investigate disorders characterized by cortisol hypersecretion.	2004-12	16019588
Selective glucocorticoid receptor nonsteroidal ligands completely antagonize the dexamethasone mediated induction of enzymes involved in gluconeogenesis and glutamine metabolism.	2004-12	15698539
Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells.	2004-12	15358673
Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor.	2004-11	15308689
Role of cysteines 640, 656, and 661 in steroid binding to rat glucocorticoid receptors.	1992-06-05	1597467
Hormone activation of baculovirus expressed progesterone receptors.	1992-03-15	1544902
[Cardiocirculatory arrest after administration of combined mifepristone (Mifegyne) and sulprostone (Nalador) for induced abortion. Possible role of coronary vasospasm].	1992-01	1550429

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Abortion -Day One: 200 mg mifepristone (MIFEPREX) orally as a single dose -Day Two or Three: 800 mcg misoprostol buccally 24 to 48 hours after the first dose of mifepristone (Two 200 mcg misoprostol tablets should be placed in each cheek pouch [the area between the cheek and gums] for 30 minutes and then swallow any remnants with water or another liquid).

Route of Administration: Oral

In Vitro Use Guide

Exposure to a low concentration (0.5uM) of mifepristone during the receptive period successfully inhibits human embryo implantation process in vitro.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:02:17 GMT 2025` Edited by `admin` on `Wed Apr 02 09:02:17 GMT 2025`
Record UNII	320T6RNW1F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

(11?,17?)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(1-propyn-1-yl)estra-4,9-dien-3-one

Preferred Name

English

MIFEPRISTONE

Official Name

English

RU 486

Code

English

MIFEPRISTONE [JAN]

Common Name

English

mifepristone [INN]

Common Name

English

MIFEGYNE

Common Name

English

MIFEPRISTONE [MI]

Common Name

English

17?-Hydroxy-11?-[4-(dimethylamino)-phenyl]-17?-(prop-1-ynyl)-estra-4,9-dien-3-one

Systematic Name

English

RU486

Code

English

MIFEPRISTONE [MART.]

Common Name

English

NSC-759862

Code

English

RU 38486

Code

English

MIFEPRISTONE [USAN]

Common Name

English

MIFEPRISTONE [HSDB]

Common Name

English

MIFEPRISTONE [VANDF]

Common Name

English

MIFEPREX

Brand Name

English

RU-486

Code

English

MIFEPRISTONE [USP-RS]

Common Name

English

Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propyn-1-yl)-, (11?,17?)-

Systematic Name

English

KORLYM

Brand Name

English

Mifepristone [WHO-DD]

Common Name

English

MIFEPRISTONE [ORANGE BOOK]

Common Name

English

RU-38486

Code

English

Classification Tree Code System Code

NDF-RT

N0000000115